SOURCE: HeartStitch®


December 21, 2015 15:00 ET

HeartStitch® Lectures at CSI 2015 - Structural Heart Congress, Frankfurt Germany

Prof. Anthony Nobles Introduces Porcine Clinical Results of HeartStitch® TA and HeartStitch® MR

LOS ANGELES, CA--(Marketwired - Dec 21, 2015) - The HeartStitch® 'tradition' of important announcements every year at CSI continued this year as Prof. Nobles, HeartStitch® CEO, lectured on the clinical results generated by the company's latest devices. These latest clinical results underscored HeartStitch's solid reputation for innovation; uncomplicated, cardiologist-focused design; and sheer effectiveness. 

As the HeartStitch® TA has continued its transition to commercialization, each milestone has served to further energize its quickly growing international team. President Ben Brosch said, "The annual CSI meeting has always been a significant meeting for the company. HeartStitch® is launching into sales mode -- with new product lines available in Europe and soon to be marketed in the United States."

Dirk Segers, HeartStitch's VP of Sales and Marketing, discussed the importance of the conference, and the product launch world wide: "The CSI conference is the most significant place to introduce a product for structural heart, and we intend to expand our portfolio and present at CSI Dubai and Frankfurt in 2016."

HeartStitch® has traditionally used CSI as a hands-on familiarization opportunity for Europe's top cardiologists, and this year was no exception. During a two-day period at the conference, HeartStitch's licensed NobleStitch™ technology was further presented through its training HUB where Dr. Michael Mullen (UK), Dr. John Crew (USA), Prof. Anthony Nobles, and Dr. Hasan (USA) trained several of the top interventional cardiologists on how to perform a closure procedure using the NobleStitch™ EL device.

About HeartStitch®
HeartStitch® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace. HeartStitch® is focused on the innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

The HeartStitch® TA and HeartStitch® MR are FDA cleared for vascular suturing in the United States. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States and CE Marked for cardio-vascular suturing and PFO closure in the European Union.

For more on HeartStitch® visit

Contact Information